Management plan to save the eel. Optimising the design and management of installations

The European eel was until recently an abundant species in most European freshwaters, but its numbers have fallen sharply since the 1970s and 1980s. The causes of the rapid decline, which now threatens the very existence of the species, are clear for the most part and include fishing, poor quality of water and habitats, fragmentation of rivers by weirs and dams, and death in hydroelectric turbines. To meet the restocking goals set by the European Union (EU), France has initiated a management plan addressing each of the factors responsible for the decline of the species. Concerning river obstacles and turbines, the Ecology ministry launched an R&D programme bringing together a number of partners, including Ademe, Onema and five hydroelectric companies, namely Compagnie nationale du Rhône, EDF, France Hydro Electricité, GDF Suez and Société hydroélectrique du Midi. The programme, managed by a steering committee comprising the partners mentioned above and placed under the responsibility of the Ecology ministry, targeted a number of operational goals that resulted in the development and testing of technical solutions designed for rapid implementation in the field. All programme results were presented on 28 and 29 November 2011 at the feedback symposium which brought together 160 persons, including researchers, water managers, associations and hydroelectric companies

Plan de sauvegarde de l'anguille. Quelles solutions pour optimiser la conception et la gestion des ouvrages ?

Hier encore très répandue dans plupart des eaux douces d’Europe, l'anguille européenne connaît une régression rapide depuis les années 1970-1980. Les causes de ce déclin brutal, qui menace désormais la pérennité de l’espèce, sont pour l'essentiel connues : prélèvements par la pêche, dégradation de la qualité des eaux et des habitats, fragmentation des rivières sous l'effet des seuils et barrages et mortalités lors des passages dans les turbines hydroélectriques. Pour répondre aux objectifs de restauration des stocks fixés par l'Union européenne, la France s'est engagée dans un plan de gestion visant à agir sur chacun des facteurs de déclin de l'espèce. Sur le volet «ouvrages», le Ministère en charge de Développement durable a initié un programme de recherche & développement multi-partenarial, réunissant l'Ademe, l'Onema et cinq acteurs français de l’hydoéléctricité : Compagnie Nationale du Rhône, EDF, France Hydro Électricité, GDF Suez, Société hydroélectrique du Midi. Résolument opérationnel, ce programme, encadré par un comité de pilotage rassemblant les acteurs précédemment cités et placé sous l'autorité du MEDDE, s'est traduit par la mise au point et le test de solutions techniques en vue d’une mise en oeuvre directe sur les territoires. L'ensemble de ces acquis ont été présentés lors d’un colloque les 28 et 29 novembre 2011 qui a rassemblé près de 160 personnes : scientifiques, gestionnaires de l’eau, associations, producteurs d’hydroélectricité

Hardware Engines for Bus Encryption: a Survey of Existing Techniques

International audienceHardware Engines for Bus Encryption: a Survey of Existing Technique

Wear generated by sliding impacts

Vibrations of the steam generator tubes in nuclear power plants induce stochastic impacts between the tubes and their supports. As a consequence, wear is generated. A test rig is designed and used to perform impacts between two metal crossed cylinders with various incidence angles and impact velocities. The normal and tangential components of the contact load are measured during the tests. Rate and duration of impacts, instantaneous ratio between normal and tangential loads for each impact are deduced. Influence of incidence angle and impact velocity on impact duration, ratio between tangential and normal loads during impact and wear volume is highlighted

UPPER TRIASSIC CALCAREOUS ALGAE FROM THE PANTHALASSA OCEAN

Upper Triassic calcareous algae, abundant and well-diversified in Tethyan deposits, have rarely been described in rocks of Panthalassan origin. Over the past ten years, several studies were performed on Upper Triassic carbonate deposits of Panthalassan affinity in North America, Japan and Far East Russia, revealing unexpectedly rich and diversified assemblages. The samples were collected from nine localities situated on both sides of the Pacific Ocean. The identified algal assemblage consists of green and red algae, including fourteen dasycladaleans, rare bryopsidaleans, and several rhodophyceans. This paper describes the main algal taxa, including six new species: Holosporella? rossanae Bucur & Del Piero n. sp., Holosporella magna Bucur & Fucelli n. sp., Griphoporella minuta Bucur & Peybernes n. sp., Patruliuspora pacifica Bucur, Del Piero & Peyrotty n. sp., Patruliuspora oregonica Bucur & Rigaud n. sp. and Collarecodium? nezpercae Bucur & Rigaud n. sp. Rivulariacean-like cyanobacteria and thaumatoporellacean algae are also present. The whole Panthalassan algal assemblage comprises both unknown (?endemic) and common taxa of the Tethyan domain. To explain the cosmopolitan distribution of various Upper Triassic benthic organisms scleractinian corals, calcified sponges, foraminifera), a close connection with the Tethys Ocean was hypothesized by different authors. During the Late Triassic, the Tethys was open to the east on the Western Panthalassa but not to the west, suggesting that Triassic calcareous algae were able to efficiently colonize environments that are estimated to be more than 10’000 km apart. An adventitious transport of calcareous algae and/or their spores is proposed to explain this long-range algal dispersal

Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

Introduction: The PENELOPE trial evaluated pertuzumab added to chemotherapy for biomarker-selected platinum-resistant ovarian cancer. As previously reported, pertuzumab did not statistically significantly improve progression-free survival (primary end point: HR 0.74, 95% CI 0.50 to 1.11), although results in the paclitaxel and gemcitabine cohorts suggested activity. Here, we report final overall survival and patient-reported outcomes. Patients and methods: Eligible patients had ovarian carcinoma that progressed during/within 6 months of completing ≥4 platinum cycles, low tumor human epidermal growth factor receptor 3 (HER3) mRNA expression, and ≤2 prior chemotherapy lines. Investigators selected single-agent topotecan, gemcitabine or weekly paclitaxel before patients were randomized to either placebo or pertuzumab (840→420 mg every 3 weeks), stratified by selected chemotherapy, prior anti-angiogenic therapy, and platinum-free interval. Final overall survival analysis (key secondary end point) was pre-specified after 129 deaths. Patient-reported outcomes (secondary end point) were assessed at baseline and every 9 weeks until disease progression. Results: At database lock (June 9, 2016), 130 (83%) of 156 randomized patients had died. Median follow-up was 27 months in the pertuzumab arm versus 26 months in the control arm. In the intent-to-treat population there was no overall survival difference between treatment arms (stratified HR 0.90, 95% CI 0.61 to 1.32; p=0.60). Results in subgroups defined by stratification factors indicated heterogeneity similar to previous progression-free survival results. Updated safety was similar to previously published results. Compliance with patient-reported outcomes questionnaire completion was >75% for all validated patient-reported outcomes measures. Pertuzumab demonstrated neither beneficial nor detrimental effects on patient-reported outcomes compared with placebo, except for increased diarrhea symptoms. Discussion: Consistent with the primary results, adding pertuzumab to chemotherapy for low tumor HER3 mRNA-expressing platinum-resistant ovarian cancer did not improve overall survival, but showed trends in some cohorts. Except for increased diarrhea symptoms, pertuzumab had no impact on patient-reported outcomes. ClinicalTrials.gov: ClinicalTrials.gov: NCT01684878

Comprehensive analysis of constitutional mismatch repair deficiency-associated non-Hodgkin lymphomas in a global cohort

BACKGROUND: Constitutional mismatch repair deficiency syndrome (CMMRD) is a rare childhood cancer predisposition syndrome associated with a broad spectrum of malignancies, including non-Hodgkin lymphomas (NHL). Most patients die due to cancer before the age of 20 years. Limited data exist on CMMRD-associated lymphomas and their outcome.METHODS: We conducted a retrospective study including all CMMRD-associated NHL patients registered before 2020 in the European and North American databases or reported by members of the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL). Events considered to define event-free survival included relapse/progression, second malignancy (SML), or death, whichever occurred first.FINDINGS: The analysis included 74 patients, with 20 having multiple metachronous NHL. The median age at diagnosis was 9.4 years. Previous malignancies were reported in 36% of the patients, café au lait spots in 96%, and consanguinity in 54%. The initial lymphoma subtypes were 53 T-cell lymphoblastic lymphomas (T-LBL), four B-lymphoblastic lymphomas, and 17 mature B-cell non-Hodgkin lymphoma (B-NHL). All patients were treated with curative intent, with current chemotherapy regimens adapted to their subtype. The median follow-up was 8.7 years. After the first lymphoma, the 5-year event-free and overall survival rates were, respectively, 23.5% [95% confidence interval (CI): 14.9-35.1] and 61.5% [95% CI: 49.6-72.1]. The 5-year cumulative risk of progression/relapse, SML or death as a first event was 20.8%, 52.9%, and 2.7%.INTERPRETATION: Standard treatments for sporadic NHL are effective in most CMMRD-associated NHL cases, but multiple malignancies, including lymphomas, impair prognosis. Future strategies should evaluate the potential of less genotoxic therapies, including immunotherapy, in preventing SMLs while maintaining effective control of NHL.</p

Comprehensive analysis of constitutional mismatch repair deficiency-associated non-Hodgkin lymphomas in a global cohort

BACKGROUND: Constitutional mismatch repair deficiency syndrome (CMMRD) is a rare childhood cancer predisposition syndrome associated with a broad spectrum of malignancies, including non-Hodgkin lymphomas (NHL). Most patients die due to cancer before the age of 20 years. Limited data exist on CMMRD-associated lymphomas and their outcome.METHODS: We conducted a retrospective study including all CMMRD-associated NHL patients registered before 2020 in the European and North American databases or reported by members of the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL). Events considered to define event-free survival included relapse/progression, second malignancy (SML), or death, whichever occurred first.FINDINGS: The analysis included 74 patients, with 20 having multiple metachronous NHL. The median age at diagnosis was 9.4 years. Previous malignancies were reported in 36% of the patients, café au lait spots in 96%, and consanguinity in 54%. The initial lymphoma subtypes were 53 T-cell lymphoblastic lymphomas (T-LBL), four B-lymphoblastic lymphomas, and 17 mature B-cell non-Hodgkin lymphoma (B-NHL). All patients were treated with curative intent, with current chemotherapy regimens adapted to their subtype. The median follow-up was 8.7 years. After the first lymphoma, the 5-year event-free and overall survival rates were, respectively, 23.5% [95% confidence interval (CI): 14.9-35.1] and 61.5% [95% CI: 49.6-72.1]. The 5-year cumulative risk of progression/relapse, SML or death as a first event was 20.8%, 52.9%, and 2.7%.INTERPRETATION: Standard treatments for sporadic NHL are effective in most CMMRD-associated NHL cases, but multiple malignancies, including lymphomas, impair prognosis. Future strategies should evaluate the potential of less genotoxic therapies, including immunotherapy, in preventing SMLs while maintaining effective control of NHL.</p

Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome : Insights from the LUNG SAFE study

Publisher Copyright: © 2020 The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.Background: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. Methods: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≥ 0.60 during hyperoxemia). Results: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). Conclusions: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. Trial registration: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073publishersversionPeer reviewe

Relationship between the Clinical Frailty Scale and short-term mortality in patients ≥ 80 years old acutely admitted to the ICU: a prospective cohort study.

BACKGROUND: The Clinical Frailty Scale (CFS) is frequently used to measure frailty in critically ill adults. There is wide variation in the approach to analysing the relationship between the CFS score and mortality after admission to the ICU. This study aimed to evaluate the influence of modelling approach on the association between the CFS score and short-term mortality and quantify the prognostic value of frailty in this context. METHODS: We analysed data from two multicentre prospective cohort studies which enrolled intensive care unit patients ≥ 80 years old in 26 countries. The primary outcome was mortality within 30-days from admission to the ICU. Logistic regression models for both ICU and 30-day mortality included the CFS score as either a categorical, continuous or dichotomous variable and were adjusted for patient's age, sex, reason for admission to the ICU, and admission Sequential Organ Failure Assessment score. RESULTS: The median age in the sample of 7487 consecutive patients was 84 years (IQR 81-87). The highest fraction of new prognostic information from frailty in the context of 30-day mortality was observed when the CFS score was treated as either a categorical variable using all original levels of frailty or a nonlinear continuous variable and was equal to 9% using these modelling approaches (p < 0.001). The relationship between the CFS score and mortality was nonlinear (p < 0.01). CONCLUSION: Knowledge about a patient's frailty status adds a substantial amount of new prognostic information at the moment of admission to the ICU. Arbitrary simplification of the CFS score into fewer groups than originally intended leads to a loss of information and should be avoided. Trial registration NCT03134807 (VIP1), NCT03370692 (VIP2)